Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 17.00% is 46% above its 5-year average of 11.64%, near the high end of its 5-year range (0.17%–17.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.45% above its 12-month average of 15.12%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.00%.
DEBT TO ASSETS RATIO
17.00%
DEBT TO ASSETS RATIO AVG TTM
15.12%
DEBT TO ASSETS RATIO AVG 3Y
12.47%
DEBT TO ASSETS RATIO AVG 5Y
11.64%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+12.45%
CURRENT VS 3Y AVG
+36.42%
CURRENT VS 5Y AVG
+46.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+18794.38%
vs the sector median at left
Nautilus Biotechnolgy, Inc.
Market Cap
$225.24M
Debt to Assets Ratio
17.00%
TTM Avg
15.12%
3Y Avg
12.47%
5Y Avg
11.64%
Market Cap
$220.93M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$231.77M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$218.30M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$216.91M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $225.24M | 17.00% | 15.12% | 12.47% | 11.64% |
| Biodesix, Inc. (BDSX)vs › | $227.60M | 0.75% | N/A | N/A | N/A |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | 0.12% | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | 0.10% | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | 0.00% | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | 0.05% | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | 0.00% | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 0.09% | N/A | N/A | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 0.00% | N/A | N/A | N/A |
Debt/Assets
17.0%
Debt/Equity
0.21
Current Ratio
10.14
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 17.00% |
| 2026-03-31 | 16.24% |
| 2025-12-31 | 15.71% |
| 2025-09-30 | 13.44% |
| 2025-06-30 | 13.22% |
| 2025-03-31 | 12.89% |
| 2024-12-31 | 12.56% |
| 2024-09-30 | 12.15% |
| 2024-06-30 | 11.95% |
| 2024-03-31 | 11.65% |
| 2023-12-31 | 11.33% |
| 2023-09-30 | 11.19% |
| 2023-06-30 | 11.02% |
| 2023-03-31 | 10.79% |
| 2022-12-31 | 8.66% |
| 2022-09-30 | 8.12% |
| 2022-06-30 | 7.97% |
| 2022-03-31 | 7.81% |
| 2021-12-31 | 7.54% |
| 2021-09-30 | 0.94% |
| 2021-06-30 | 0.17% |
| 2021-03-31 | 1.67% |
| 2020-12-31 | 5.62% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 30.01% |
| 2019-12-31 | 1483.12% |
| 2019-09-30 | 91.16% |
| 2019-06-30 | 29.17% |
| 2019-03-31 | 29.34% |
| 2018-12-31 | 3.43% |
